Related to Accumetrics Allies with Portola to Develop Clinical Test for Platelet Reactivity

• Roche Sublicenses EGFR IP from Genzyme to Develop Tarceva Companion Diagnostic
  
• Transgenomic Picks Up Clinical Data’s MDx and Biomarker Business for $15.4M
  
• Phase III Trial Finds Edoxaban Outclasses Enoxaparin in Preventing Venous Thromboembolic Events
  
• Sequenta Scores $13M Series B Financing
  
• ChipDX Finds 163-Gene Signature that Predicts Early-Stage Colon Cancer Progression
  
• AltheaDx and Compendia Launch Breast Cancer Segregation Panel
  
• Myriad Takes Over Testing Platform from Melanoma Diagnostics
  
• MDxHealth Sets Up Companion Diagnostics Unit to Collaborate with Ghent University
  
• Beckman Coulter to Develop aNK Assay for Pivotal Trial of Transgene’s NSCLC Drug
  
• Investigators Identify Prognostic Marker for Treating Hep C with Peg-Interferon and Ribavirin
  
• BG Medicine to Develop Heart Failure Test for Siemens
  
• 20-Gene Prognostic Test for Bladder Cancer Developed
  
• Novartis to Buy Personalized Diagnostics Services Firm Genoptix for $470M
  
• Walter Reed to Use DiaTech Oncology’s Assay to Study Patients’ Response to Chemotherapy
  
• Geospiza Gets $1.2M Grant to Add DNA Variant Application to GeneSifter Software
  
• Agendia Receives FDA Approval for MammaPrint Assay that Broadens Its Lab Capacity
  
• Ipsen and BioMérieux to Co-Develop Cancer Therapeutics and Companion Dx
  
• AmoyDx Gains CE Mark for EGFR, KRAS, and BRAF Tests
  
• Tussle Between Respira and Precision for Med BioGene’s NSCLC Assay Escalates
  
• Aeterna Zentaris Wins $1.5M from BMBF to Develop GPCR-Targeting Disorazol Z Conjugates